Back to top

Legend Biotech resumed with a Neutral at JPMorgan

JPMorgan resumed coverage of Legend Biotech (LEGN) with a Neutral rating and $35 price target While Carvykti has had a “healthy launch,” JPMorgan s...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Legend Biotech Corporation Sponsored ADR (LEGN)